Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
TD Cowen Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $70
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Tandem Diabetes Care (TNDM) and BioMarin Pharmaceutical (BMRN)
Edwards Lifesciences Is Maintained at In-Line by Evercore ISI Group
Edwards Lifesciences Analyst Ratings
Evercore Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $70
Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $77
Edwards Lifesciences Downgraded at Jefferies on Lower TAVR Growth
Jefferies Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Edwards Lifesciences Analyst Ratings
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Jefferies Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $70
Jefferies Downgrades Edwards Lifesciences to Hold From Buy, Adjusts Price Target to $70 From $85
Edwards Lifesciences: Hold Rating Amid TAVR Sector Challenges and Growth Constraints
BofA Securities Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $75
Truist Financial Downgrades Edwards Lifesciences(EW.US) to Hold Rating
Edwards Lifesciences Price Target Maintained With a $90.00/Share by Oppenheimer
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90